Search research articles
Contact Us
Filters
Showing results (1-10 of 134) with videos related to
Page
of 14
Sort By:
Breast Care (Basel, Switzerland)
|
November 5, 2010
Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine?
Per Eystein Lønning
The Journal of Steroid Biochemistry and Molecular Biology
|
May 23, 2021
Letter to the Editor
Per Eystein Lønning
International Journal of Clinical Oncology
|
August 31, 2002
The role of aromatase inactivators in the treatment of breast cancer
Per Eystein Lønning
Best Practice & Research. Clinical Endocrinology & Metabolism
|
December 23, 2003
Oestrogen suppression--lessons from clinical studies
Per Eystein Lønning
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
March 19, 2005
[Aromatase inhibitors in the therapy for breast cancer]
Per Eystein Lønning
Anti-Cancer Drugs
|
June 24, 2008
Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?
Per Eystein Lønning
The Lancet. Oncology
|
December 14, 2012
Lapatinib in early breast cancer--questions to be resolved
Per Eystein Lønning
Clinical Breast Cancer
|
September 2, 2008
Aromatase inhibition versus placebo
Per Eystein Lønning
Breast Cancer Research : BCR
|
January 9, 2009
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects
Per Eystein Lønning
The Journal of Steroid Biochemistry and Molecular Biology
|
March 2, 2016
Comments on paper: "Quantitative determination of estrone by liquid chromatography-tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal women" by Vihma et al
Per Eystein Lønning
Page
of 14
Search research articles
Search
Showing results (1-10 of 134) with videos related to
Sort By:
Page
of 14
Breast Care (Basel, Switzerland)
|
November 5, 2010
Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine?
Per Eystein Lønning
The Journal of Steroid Biochemistry and Molecular Biology
|
May 23, 2021
Letter to the Editor
Per Eystein Lønning
International Journal of Clinical Oncology
|
August 31, 2002
The role of aromatase inactivators in the treatment of breast cancer
Per Eystein Lønning
Best Practice & Research. Clinical Endocrinology & Metabolism
|
December 23, 2003
Oestrogen suppression--lessons from clinical studies
Per Eystein Lønning
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
March 19, 2005
[Aromatase inhibitors in the therapy for breast cancer]
Per Eystein Lønning
Anti-Cancer Drugs
|
June 24, 2008
Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?
Per Eystein Lønning
The Lancet. Oncology
|
December 14, 2012
Lapatinib in early breast cancer--questions to be resolved
Per Eystein Lønning
Clinical Breast Cancer
|
September 2, 2008
Aromatase inhibition versus placebo
Per Eystein Lønning
Breast Cancer Research : BCR
|
January 9, 2009
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects
Per Eystein Lønning
The Journal of Steroid Biochemistry and Molecular Biology
|
March 2, 2016
Comments on paper: "Quantitative determination of estrone by liquid chromatography-tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal women" by Vihma et al
Per Eystein Lønning
Page
of 14